Logo image of PMCB

PHARMACYTE BIOTECH INC (PMCB) Stock Fundamental Analysis

NASDAQ:PMCB - Nasdaq - US71715X2036 - Common Stock - Currency: USD

0.85  +0.01 (+1.19%)

After market: 0.87 +0.02 (+2.35%)

Fundamental Rating

3

Taking everything into account, PMCB scores 3 out of 10 in our fundamental rating. PMCB was compared to 550 industry peers in the Biotechnology industry. PMCB has a great financial health rating, but its profitability evaluates not so good. PMCB has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year PMCB was profitable.
In the past year PMCB has reported a negative cash flow from operations.
In the past 5 years PMCB always reported negative net income.
In the past 5 years PMCB always reported negative operating cash flow.
PMCB Yearly Net Income VS EBIT VS OCF VS FCFPMCB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

The Return On Assets of PMCB (19.70%) is better than 97.27% of its industry peers.
The Return On Equity of PMCB (21.45%) is better than 96.55% of its industry peers.
Industry RankSector Rank
ROA 19.7%
ROE 21.45%
ROIC N/A
ROA(3y)-13.12%
ROA(5y)-29.88%
ROE(3y)-18.09%
ROE(5y)-36.53%
ROIC(3y)N/A
ROIC(5y)N/A
PMCB Yearly ROA, ROE, ROICPMCB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PMCB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PMCB Yearly Profit, Operating, Gross MarginsPMCB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

PMCB has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, PMCB has more shares outstanding
PMCB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PMCB Yearly Shares OutstandingPMCB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
PMCB Yearly Total Debt VS Total AssetsPMCB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -2.03, we must say that PMCB is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of PMCB (-2.03) is comparable to the rest of the industry.
There is no outstanding debt for PMCB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.03
ROIC/WACCN/A
WACCN/A
PMCB Yearly LT Debt VS Equity VS FCFPMCB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M 80M

2.3 Liquidity

PMCB has a Current Ratio of 14.20. This indicates that PMCB is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 14.20, PMCB belongs to the best of the industry, outperforming 86.36% of the companies in the same industry.
PMCB has a Quick Ratio of 14.20. This indicates that PMCB is financially healthy and has no problem in meeting its short term obligations.
PMCB's Quick ratio of 14.20 is amongst the best of the industry. PMCB outperforms 86.55% of its industry peers.
Industry RankSector Rank
Current Ratio 14.2
Quick Ratio 14.2
PMCB Yearly Current Assets VS Current LiabilitesPMCB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 170.22% over the past year.
EPS 1Y (TTM)170.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.68%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PMCB Yearly EPS VS EstimatesPMCB Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2022 -10 -20 -30

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 0.77, the valuation of PMCB can be described as very cheap.
Based on the Price/Earnings ratio, PMCB is valued cheaper than 99.45% of the companies in the same industry.
When comparing the Price/Earnings ratio of PMCB to the average of the S&P500 Index (27.11), we can say PMCB is valued rather cheaply.
Industry RankSector Rank
PE 0.77
Fwd PE N/A
PMCB Price Earnings VS Forward Price EarningsPMCB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PMCB Per share dataPMCB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PMCB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PHARMACYTE BIOTECH INC

NASDAQ:PMCB (8/13/2025, 8:00:00 PM)

After market: 0.87 +0.02 (+2.35%)

0.85

+0.01 (+1.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11 2025-08-11
Earnings (Next)09-15 2025-09-15
Inst Owners8.36%
Inst Owner Change-2.17%
Ins Owners2.7%
Ins Owner Change0%
Market Cap5.83M
Analysts43.33
Price TargetN/A
Short Float %0.17%
Short Ratio0.64
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 0.77
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.14
P/tB 0.15
EV/EBITDA N/A
EPS(TTM)1.1
EY129.41%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.33
FCFYN/A
OCF(TTM)-0.33
OCFYN/A
SpS0
BVpS5.87
TBVpS5.64
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 19.7%
ROE 21.45%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-13.12%
ROA(5y)-29.88%
ROE(3y)-18.09%
ROE(5y)-36.53%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.2
Quick Ratio 14.2
Altman-Z -2.03
F-Score7
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)170.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.68%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y28.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y51.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y51.65%
OCF growth 3YN/A
OCF growth 5YN/A